LGM
TNYA icon

Logos Global Management’s Tenaya Therapeutics TNYA Stock Holding History

Logos Global Management’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-600,000
Closed -$3.52M – 69
2023
Q2 		$3.52M Buy
+600,000
New +$3.49M 0.48% 44

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Logos Global Management's TNYA Position: Q3 2023 in Review

Logos Global Management sold out of Tenaya Therapeutics (TNYA) in Q3 2023, closing a stake of 600,000 shares — an estimated $3.52M sold.

Logos Global Management first reported a position in TNYA in Q2 2023 and held it in 1 quarter. The position peaked at $3.52M in Q2 2023. 76 funds tracked by Wall St. Rank hold TNYA as of Q3 2023.

  • Logos Global Management reported no remaining Tenaya Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Logos Global Management sold 600,000 Tenaya Therapeutics shares in Q3 2023, an estimated $3.52M.
  • Logos Global Management first reported a position in Tenaya Therapeutics in Q2 2023 and held it in 1 quarter.
  • Logos Global Management's Tenaya Therapeutics position peaked at $3.52M in Q2 2023.
  • 76 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2023.

Based on Logos Global Management's 13F filing for Q3 2023, filed 14 Nov 2023.